The top 10 drug launches of 2017

Only 22 meds were greenlighted by the FDA in 2016, but no matter what tally the industry amasses this year, the crop will bring some would-be blockbusters and market disrupters.
Novo Nordisk

Novo's new GLP-1 semaglutide slashes heart risks by 26%

Novo Nordisk's blockbuster GLP-1 diabetes drug Victoza has been losing market share to new rival Trulicity and its convenient weekly dosing. But Novo could regain its edge yet: It has a weekly follow-up in the works, semaglutide, and on Friday, that drug showed it could cut cardiovascular risks by 26%.